%0 Journal Article %T In vivo MEMRI characterization of brain metastases using a 3D Look-Locker T1-mapping sequence %+ Centre de résonance magnétique des systèmes biologiques (CRMSB) %+ Institut de physiologie et biologie cellulaires (IPBC) %A Castets, Charles %A Koonjoo, Neha %A Hertanu, Andreea %A Voisin, Pierre %A Franconi, Jean-Michel %A Miraux, Sylvain %A Ribot, Emeline %< avec comité de lecture %@ 2045-2322 %J Scientific Reports %I Nature Publishing Group %V 6 %N 1 %8 2016-12 %D 2016 %R 10.1038/srep39449 %Z Life Sciences [q-bio]Journal articles %X Although MEMRI (Manganese Enhanced MRI) informations were obtained on primary tumors in small animals, MEMRI data on metastases are lacking. Thus, our goal was to determine if 3D Look-Locker T1 mapping was an efficient method to evaluate Mn ions transport in brain metastases in vivo. The high spatial resolution in 3D (156 × 156 × 218 μm) of the sequence enabled to detect metastases of 0.3 mm 3. In parallel, the T1 quantitation enabled to distinguish three populations of MDA-MB-231 derived brain metastases after MnCl2 intravenous injection: one with a healthy blood-tumor barrier that did not internalize Mn 2+ ions, and two others, which T1 shortened drastically by 54.2% or 24%. Subsequent scans of the mice, enabled by the fast acquisition (23 min), demonstrated that these T1 reached back their pre-injection values in 24 h. Contrarily to metastases, the T1 of U87-MG glioma remained 26.2% shorter for one week. In vitro results supported the involvement of the Transient Receptor Potential channels and the Calcium-Sensing Receptor in the uptake and efflux of Mn 2+ ions, respectively. This study highlights the ability of the 3D Look-Locker T1 mapping sequence to study heterogeneities (i) amongst brain metastases and (ii) between metastases and glioma regarding Mn transport. %G English %2 https://cnrs.hal.science/hal-02404151/document %2 https://cnrs.hal.science/hal-02404151/file/srep39449.pdf %L hal-02404151 %U https://cnrs.hal.science/hal-02404151 %~ CNRS %~ UNIV-POITIERS %~ CRMSB %~ STIM